First FDA-approved cannabis-based drug now available in the US

Epidiolex, the first cannabis-based medication approved by the US Food and Drug Administration, is now avail...

Posted: Nov 2, 2018 1:49 PM
Updated: Nov 2, 2018 1:49 PM

Epidiolex, the first cannabis-based medication approved by the US Food and Drug Administration, is now available by prescription in all 50 states.

The twice-daily oral solution is approved for use in patients 2 and older to treat two types of epileptic syndromes: Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life, and Lennox-Gastaut syndrome, a form of epilepsy with multiple types of seizures that begins in early childhood, usually between ages 3 and 5.

Continents and regions

North America

The Americas

United States

Government organizations - US

US Department of Health and Human Services

US federal departments and agencies

US Food and Drug Administration

Controlled substances

Drugs and society

Marijuana

Society

Alternative medicine

Health and medical

Medical marijuana

Business and industry sectors

Business, economy and trade

Chronic diseases

Diseases and disorders

Drug safety

Drug safety, efficacy and availability

Epilepsy

Medical fields and specialties

Medical research

Neurological disorders and injuries

Pharmaceuticals and biotechnology

Drug prices

Health care

Health care costs

Pharmaceutical industry

Pharmaceuticals and prescription drugs

"Because these patients have historically not responded well to available seizure medications, there has been a dire need for new therapies that aim to reduce the frequency and impact of seizures," said Justin Gover, CEO of GW Pharmaceuticals, the maker of Epidiolex, in a written statement. "We are committed to ensuring that these patients can access this novel cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and is eligible to be covered by insurance for appropriate patients."

Epidiolex was recommended for approval by an advisory committee in April and approved by the FDA in June. In September, the US Department of Justice and the Drug Enforcement Administration classified Epidiolex as a Schedule V substance, clearing the final hurdle for it to be legally prescribed by doctors in the United States. (Marijuana and CBD remain Schedule I substances.)

"Adequate and well-controlled clinical studies supported Epidiolex's approval, so prescribers can have confidence in the drug's uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes," FDA Commissioner Dr. Scott Gottlieb said in a written statement. "The FDA will continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and stand ready to work with product developers who are interested in bringing patients safe and effective, high quality products."

Dr. Orrin Devinsky, director of the Comprehensive Epilepsy Center at NYU Langone Health, served as the lead investigator of two of three phase three clinical trials of Epidiolex.

"In those syndromes, when [Epidiolex] was added to three other seizure [medications], on average, it reduced convulsive seizures -- or 'drop seizures' -- by about 25% to 28% compared to a placebo," Devinsky said. "So I think it's very important to recognize ... that it clearly is effective, and this was statistically significant in all three of the large studies that we did, but by the same token, the effect was modest.

"There are some people who had dramatic improvements. Many had a modest improvement, and some had no improvement. So it's not a miracle drug. It's an effective drug, and I think its side effect profile is quite good compared to other seizure drugs that we have, but it's not a miracle cure," Devinsky said.

The most common side effects of Epidiolex, according to GW Pharmaceuticals, include sleepiness, decreased appetite, diarrhea and an increase in liver enzymes.

Shauna Garris, a pharmacist, pharmacy clinical specialist and adjunct assistant professor at the University of North Carolina's Eshelman School of Pharmacy, said the drug is effective and works somewhere between "fairly" and "very well." She has not used Epidiolex in her own clinical practice and was not involved in the development of the drug but said she's not sure it will live up to "all of the hype" that has surrounded it.

Still, she said the FDA's approval of Epidiolex signals "validation of the science of cannabinoid medication."

GW Pharmaceuticals says the average list price of Epidiolex is $32,500 a year. The company expects that the drug will be covered by most insurance plans and asserts that "this price is in line with other branded, FDA-approved anti-epileptic drugs (AEDs), such as Banzel, and access for eligible patients is expected to be similar to such AEDs for similar indications for LGS (e.g., Onfi and Banzel)."

It is also launching a patient support program "to help patients who have been prescribed Epidiolex gain access to therapy. The program offers patient/caregiver-focused education and resources to help lower out-of-pocket costs or provide product at no cost for eligible patients."

Although Epidiolex is approved only for the treatment of two rare seizure disorders, doctors can now prescribe the medication "off-label" for other conditions. According to the US Department of Health and Human Services, this is both legal and common; one in five of all medications prescribed is for off-label use.

"The off-label use of CBD and Epidiolex will be a fascinating subject to look at over the coming years," Devinsky said. "Many, many patients would like to have access to it who don't fit the criteria, and I believe many doctors will try to prescribe it, as will I for some people who I think have tried many, many medications and for whom it might be beneficial."

He added, "I think doctors are always trying to make those decisions about a good benefit-to-toxicity ratio, and CBD is a fairly attractive compound. The question is, what will the insurance companies do?"

Minnesota Coronavirus Cases

Data is updated nightly.

Cases: 591445

Reported Deaths: 7367
CountyCasesDeaths
Hennepin1224421730
Ramsey51212875
Dakota45791452
Anoka41604438
Washington26834283
Stearns22196222
St. Louis17734303
Scott17244124
Wright16009139
Olmsted1322598
Sherburne1167187
Carver1047545
Clay814492
Rice8037107
Blue Earth749641
Crow Wing663189
Kandiyohi654283
Chisago596651
Otter Tail574078
Benton568297
Goodhue477272
Douglas466375
Mower464832
Winona453950
Itasca435556
McLeod422559
Isanti419664
Morrison418260
Nobles407648
Beltrami394459
Steele386715
Polk383568
Becker379751
Lyon360251
Carlton345054
Freeborn341529
Pine327822
Nicollet325643
Brown305040
Mille Lacs303253
Le Sueur290922
Todd281632
Cass271328
Meeker255740
Waseca235922
Martin230531
Roseau209019
Wabasha20513
Hubbard188341
Dodge18453
Renville179743
Redwood174037
Houston171616
Cottonwood164821
Fillmore155910
Wadena155922
Pennington153619
Chippewa152138
Faribault152119
Kanabec144326
Sibley143110
Aitkin134736
Watonwan13219
Rock128119
Jackson121712
Pipestone115426
Yellow Medicine114120
Pope11006
Murray10619
Swift105218
Stevens90411
Marshall88117
Clearwater86616
Koochiching82715
Wilkin81112
Lake80919
Lac qui Parle75222
Big Stone6004
Lincoln5813
Grant5748
Mahnomen5469
Norman5399
Unassigned48993
Kittson48622
Red Lake3957
Traverse3695
Lake of the Woods3243
Cook1620

Iowa Coronavirus Cases

Data is updated nightly.

Cases: 366827

Reported Deaths: 5937
CountyCasesDeaths
Polk57596625
Linn20845335
Scott20025241
Black Hawk15803308
Woodbury15128228
Johnson1447483
Dubuque13368208
Dallas1117898
Pottawattamie11113168
Story1061248
Warren577088
Clinton555593
Cerro Gordo539789
Sioux514474
Webster512393
Marshall482975
Muscatine480799
Des Moines455766
Wapello4299122
Buena Vista424540
Jasper418872
Plymouth401180
Lee375755
Marion362575
Jones298957
Henry291637
Carroll285752
Bremer284360
Crawford266440
Boone264534
Benton256455
Washington254150
Dickinson248343
Mahaska230351
Jackson221742
Clay215525
Kossuth215364
Delaware209541
Tama209571
Winneshiek196834
Page192622
Buchanan191232
Cedar190023
Hardin185243
Fayette185041
Wright184637
Hamilton179849
Harrison179573
Clayton169456
Butler164934
Mills162322
Madison162219
Floyd160542
Cherokee158738
Lyon157941
Poweshiek154734
Allamakee151551
Iowa148724
Hancock147834
Winnebago142431
Cass138554
Calhoun138413
Grundy136333
Emmet134140
Jefferson132335
Shelby131037
Sac130319
Union128333
Louisa128049
Appanoose127949
Mitchell126342
Chickasaw124015
Guthrie121530
Franklin120021
Humboldt119126
Palo Alto112723
Howard104622
Montgomery103338
Clarke100124
Unassigned9710
Keokuk95831
Monroe95229
Ida90535
Adair86532
Pocahontas85522
Davis82924
Monona82830
Osceola78616
Greene77610
Lucas77323
Worth7478
Taylor65812
Fremont6229
Decatur6089
Van Buren55818
Ringgold55624
Wayne53923
Audubon51010
Adams3384
Rochester
Cloudy
56° wxIcon
Hi: 66° Lo: 48°
Feels Like: 56°
Mason City
Cloudy
54° wxIcon
Hi: 66° Lo: 44°
Feels Like: 54°
Albert Lea
Cloudy
57° wxIcon
Hi: 64° Lo: 50°
Feels Like: 57°
Austin
Cloudy
55° wxIcon
Hi: 65° Lo: 47°
Feels Like: 55°
Charles City
Cloudy
° wxIcon
Hi: 67° Lo: 42°
Feels Like: °
Warmer conditions for the weekend
KIMT Radar
KIMT Eye in the sky

Community Events